Blanche C. Ip

This study evaluates strategies to inhibit XPR1 in ovarian cancer, showing that IP6K inhibitors effectively mimic XPR1 inhibition by blocking phosphate efflux and reducing tumor burden in xenograft models.

This study identifies DNA hypomethylation, not DNA damage, as the primary mechanism of azacytidine and decitabine anti-cancer activity, linking it to chromatin regulators like USP48.